Breaking News
Sort by:
Top Post
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
ProBioGen, a Berlin-based specialist for developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines, and […]
Sobi to Acquire CTI BioPharma
CTI BioPharma, a commercial biopharmaceutical company focused on the development and commercialization of novel targeted […]
Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies
Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific […]
Vicinitas Therapeutics Appoints Christian Hofmann, Ph.D., as Chief Executive Officer
Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel […]
Maryland Stem Cell Research Commission Announces Over $14 Million in Awards to Accelerate Stem Cell Cures
The Maryland Stem Cell Research Commission is pleased to announce over $14.1 million in grant […]
Nutcracker Therapeutics Appoints Cynthia Collins, Biopharma Veteran and Former Editas Medicine CEO, to Board of Directors
Nutcracker Therapeutics, a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology […]
CardiaCare Names Ken Nelson Chairman of its Board of Directors
CardiaCare, a clinical-stage digital therapeutic company developing the world’s first non-invasive, neuromodulation wearable for atrial […]
Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging-Related Diseases
Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation technologies to reverse diseases […]
Solarea Bio Announces First Close of Series B Financing Round
Solarea Bio, a clinical-stage biotechnology company based in Cambridge, MA developing food-derived microbial-based solutions to […]
Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stage KCNQ2 Activators from Lundbeck
Neuro3 Therapeutics (Neuro3), a biotechnology company focused on the discovery and development of innovative medicines […]
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701
Eisai announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more